CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 5, 2004, Pages 298-309

  Streeter, Philip R ^a   Zhang, Xingqi ^a   Tittle, Thomas V ^a   Schön, Catherine N ^a   Weinberg, Andrew D ^a,b   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Allogeneic stem cell transplantation; CD134; Graft versus host disease; OX40

Indexed keywords

ALLOANTIGEN; CD134 ANTIGEN; CD4 ANTIGEN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELL SEPARATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HOST CELL; INHIBITION KINETICS; LEUKOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; RAT; RECIPIENT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; RATS; RATS, INBRED STRAINS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTE SUBSETS; TISSUE DISTRIBUTION;

EID: 1942520972     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.12.302     Document Type: Article

References (55)

1. Thomas E.D. Storb R. Clift R.A. et al. Bone-marrow transplantation N Engl J Med 292 1975 895-902
2. Deeg H.J. Storb R. Graft-versus-host disease: pathophysiological and clinical aspects Annu Rev Med 35 1984 11-24
3. Lazarus H.M. Vogelsang G.B. Rowe J.M. Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG) Bone Marrow Transplant 19 1997 577-600
4. Klingebiel T. Schlegel P.G. GVHD: overview on pathophysiology, incidence, clinical and biological features Bone Marrow Transplant 21suppl 2 1998 S45-S49
5. Ferrara J.L. Deeg H.J. Graft-versus-host disease N Engl J Med 324 1991 667-674
6. Korngold R. Sprent J. Graft-versus-host disease in experimental allogeneic bone marrow transplantation Proc Soc Exp Biol Med 197 1991 12-18
7. den Haan J.M.M. Sherman N.E. Blokland E. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen Science 268 1995 1476-1480
8. Warren E.H. Gavin M. Greenberg P.D. Riddell S.R. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation Curr Opin Hematol 5 1998 429-433
9. Shlomchik W.D. Couzens M.S. Tang C.B. et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412-415
10. Teshima T. Ordemann R. Reddy P. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium Nat Med 8 2002 575-581
11. Weinberg A.D. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines Trends Immunol 23 2002 102-109
12. Paterson D.J. Jefferies W.A. Green J.R. et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts Mol Immunol 24 1987 1281-1290
13. Weinberg A.D. Vella A.T. Croft M. OX-40: life beyond the effector T cell stage Semin Immunol 10 1998 471-480
14. Tittle T.V. Weinberg A.D. Steinkeler C.N. Maziarz R.T. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease Blood 89 1997 4652-4658
15. Stuber E. Neurath M. Calderhead D. Fell H.P. Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells Immunity 2 1995 507-521
16. Stuber E. Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response J Exp Med 183 1996 979-989
17. Ohshima Y. Tanaka Y. Tozawa H. Takahashi Y. Maliszewski C. Delespesse G. Expression and function of OX40 ligand on human dendritic cells J Immunol 159 1997 3838-3848
18. Brocker T. Gulbranson-Judge A. Flynn S. Riedinger M. Raykundalia C. Lane P. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles Eur J Immunol 29 1999 1610-1616
19. Godfrey W.R. Fagnoni F.F. Harara M.A. Buck D. Engleman E.G. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor J Exp Med 180 1994 757-762
20. Baum P.R. Gayle R.B. Ramsdell F. et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34 EMBO J 13 1994 3992-4001
21. Imura A. Hori T. Imada K. et al. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells J Exp Med 183 1996 2185-2195
22. Weinberg A.D. Wegmann K.W. Funatake C. Whitham R.H. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis J Immunol 162 1999 1818-1826
23. Gramaglia I. Jember A. Pippig S.D. Weinberg A.D. Killeen N. Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion J Immunol 165 2000 3043-3050
24. Chen A.I. McAdam A.J. Buhlmann J.E. et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions Immunity 11 1999 689-698
25. Rogers P.R. Song J. Gramaglia I. Killeen N. Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells Immunity 15 2001 445-455
26. De Smedt T. Smith J. Baum P. Fanslow W. Butz E. Maliszewski C. OX40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo J Immunol 168 2002 661-670
27. Rogers P.R. Croft M. CD28, OX-40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen J Immunol 164 2000 2955-2963
28. Gramaglia I. Weinberg A.D. Lemon M. Croft M. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses J Immunol 161 1998 6510-6517
29. Maxwell J.R. Weinberg A. Prell R.A. Vella A.T. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion J Immunol 164 2000 107-112
30. Bansal-Pakala P. Jember A.G. Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance Nat Med 7 2001 907-912
31. Weatherill A.R. Maxwell J.R. Takahashi C. Weinberg A.D. Vella A.T. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo Cell Immunol 209 2001 63-75
32. Evans D.E. Prell R.A. Thalhofer C.J. Hurwitz A.A. Weinberg A.D. Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4 J Immunol 167 2001 6804-6811
33. Tsukada N. Akiba H. Kobata T. Aizawa Y. Yagita H. Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation Blood 95 2000 2434-2439
34. Lamb Jr. L.S. Abhyankar S.A. Hazlett L. et al. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease Cytometry 38 1999 238-243
35. Gadisseur A.P. Gratama J.W. Lamers C. van Esser J.W. Bolhuis R.L. Cornelissen J.J. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation Bone Marrow Transplant 23 1999 1013-1017
36. Kotani A. Ishikawa T. Matsumura Y. et al. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation Blood 98 2001 3162-3164
37. Blazar B.R. Sharpe A.H. Chen A.I. et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients Blood 101 2003 3741-3748
38. Schwart R.H. T cell anergy Annu Rev Immunol 21 2003 305-334
39. Baker M.B. Altman N.H. Podack E.R. Levy R.B. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice J Exp Med 183 1996 2645-2656
40. Braun M.Y. Lowin B. French L. Acha-Orbea H. Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease J Exp Med 183 1996 657-661
41. Hattori K. Hirano T. Miyajima H. et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies Blood 91 1998 4051-4055
42. Graubert T.A. DiPersio J.F. Russell J.H. Ley T.J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation J Clin Invest 100 1997 904-911
43. Mori T. Nishimura T. Ikeda Y. Hotta T. Yagita H. Ando K. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression Blood 92 1998 101-107
44. Hill G.R. Teshima T. Gerbitz A. et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia J Clin Invest 104 1999 459-467
45. Sakaguchi S. Sakaguchi N. Shimizu J. et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance Immunol Rev 182 2001 18-32
46. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers Nat Rev Immunol 2 2002 389-400
47. Roncarolo M.G. Bacchetta R. Bordignon C. Narula S. Levings M.K. Type 1 T regulatory cells Immunol Rev 182 2001 68-79
48. Cohen J.L. Trenado A. Vasey D. Klatzmann D. Salomon B.L. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease J Exp Med 196 2002 401-406
49. Hoffmann P. Ermann J. Edinger M. Fathman C.G. Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation J Exp Med 196 2002 389-399
50. Taylor P.A. Lees C.J. Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality Blood 99 2002 3493-3499
51. Queen C. Schneider W.P. Selick H.E. et al. A humanized antibody that binds to the interleukin 2 receptor Proc Natl Acad Sci U S A 86 1989 10029-10033
52. Junghans R.P. Waldmann T.A. Landolfi N.F. Avdalovic N.M. Schneider W.P. Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders Cancer Res 50 1990 1495-1502
53. Depper J.M. Leonard W.J. Robb R.J. Waldmann T.A. Greene W.C. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation J Immunol 131 1983 690-696
54. Przepiorka D. Kernan N.A. Ippoliti C. et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease Blood 95 2000 83-89
55. Waldmann T.A. The IL-2/IL-15 receptor systems: targets for immunotherapy J Clin Immunol 22 2002 51-56